Ensysce Biosciences Inc.

3.44
-0.12 (-3.37%)
At close: Mar 21, 2025, 3:57 PM
3.35
-2.62%
After-hours: Mar 21, 2025, 06:46 PM EDT
-3.37%
Bid 3.35
Market Cap 4.83M
Revenue (ttm) 557.34K
Net Income (ttm) -9.13M
EPS (ttm) -11.45
PE Ratio (ttm) -0.3
Forward PE -0.7
Analyst n/a
Ask 4.33
Volume 22,590
Avg. Volume (20D) 42,742
Open 3.56
Previous Close 3.56
Day's Range 3.30 - 3.56
52-Week Range 2.12 - 14.67
Beta 0.65

About ENSC

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 14, 2018
Employees 7
Stock Exchange NASDAQ
Ticker Symbol ENSC
Full Company Profile

Next Earnings Release

Ensysce Biosciences Inc. is scheduled to release its earnings on Mar 25, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+14.48%
Ensysce Biosciences shares are trading higher afte... Unlock content with Pro Subscription
4 months ago
+5.14%
Ensysce Biosciences shares are trading higher after the company reported better-than-expected Q3 financial results.